Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
Launched by BRIGHAM AND WOMEN'S HOSPITAL · Sep 11, 2023
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
There is a crisis in the treatment of the imminently suicidal patient. Acute Suicidal Depression (ASD) is a life-threatening illness which requires rapid relief. A number of behavioral programs with varying efficacy are available for prevention of suicide. However, once acute suicidal depression has set in, its treatment is woefully inadequate in the current health system despite availability of efficacious treatments. Patients suffering from ASD are usually admitted as inpatients for safety and started on oral antidepressants (which can take 6 - 12 weeks to have an effect) and given nursin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Considered by a clinician as appropriate for referral to treatment services for rapid reversal of acute suicidal depression.
- • Adults 18 - 90 years of age.
- • Meet DSM-5 criteria for Major Depressive Episode (MDE) as determined by Mini International Neuropsychiatric Interview (MINI PLUS 5.0.0).
- • Acute suicidal ideation or behavior (thinking or behavior suggesting harming or hurting oneself with knowledge that death may result) or attempt (any intentional, non-fatal self-injury regardless of medical lethality, if intent to die was indicated).
- • Continue to express suicidal ideation since referral as evidenced by Scale for Suicidal Ideation (SSI) ≥6)
- • Meet the following criteria on symptom rating scales at screening: Hamilton Depression Scale (HAM-D 17) \>15 and Montreal Cognitive Assessment (MoCA) of ≥23(to rule out baseline significant cognitive impairment)
- Exclusion Criteria:
- • Meeting DSM-5 criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder.
- • Not able to give informed consent to receive ECT or KET treatment.
- • Not able to give informed consent to participate in the study.
- • Meet exclusion criteria for ECT treatment as described in guidelines.
- * Meet exclusion criteria for KET treatment such as:
- • Pregnant or breast feeding
- • Satisfying DSM-V criteria of current Mood Depressive Disorder Episode with Psychotic Features (i.e. delusions of hallucinations)
- • Severe uncontrolled medical illness
- • Ketamine allergy
- • Intellectual disability and unable to provide consent or follow study procedures.
About Brigham And Women's Hospital
Brigham and Women's Hospital (BWH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As an integral part of the Partners HealthCare system, BWH combines cutting-edge medical education with a focus on patient-centered care, fostering an environment that promotes groundbreaking clinical trials across various specialties. The hospital is dedicated to translating scientific discoveries into effective treatments, making significant contributions to the fields of cardiovascular medicine, oncology, and women's health, among others. With a robust infrastructure for research and a collaborative approach, BWH aims to improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Houston, Texas, United States
Boston, Massachusetts, United States
New York, New York, United States
Baltimore, Maryland, United States
Belmont, Massachusetts, United States
Cleveland, Ohio, United States
Saint Louis, Missouri, United States
Tucson, Arizona, United States
Houston, Texas, United States
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Amit Anand, MD
Principal Investigator
Brigham and Woman's Hospital, Harvard Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported